Topics

Vice President of Life Sciences at Kenco.

Articles

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

How the Rise of Personalized Medicine Impacts Life Sciences’ Logistics

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

Keeping Drug Supplies Available Means Pharmaceutical Organizations Must Move in Real-Time 

Videos

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D. 

Decreasing Clinical Development Timelines

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

LogiPharma Europe 2025: Inside Sanofi’s Shift Toward a Data-Driven Supply Chain Model

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

How to Manage Rising Drug Development Costs

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Themes Among Rare Disease Repurposing Efforts

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Measuring What Matters

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Asembia 2025: Digital Health and Biosimilars Shape the Future of Pharmacy

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Asembia 2025: Why AI Could Be the Key to Solving Access Challenges in Healthcare

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Data & Technology